Abstract
Importance Identifying biomarkers for primary tauopathies such as progressive supranuclear palsy (PSP) is crucial for improving diagnosis and establishing clinical trial and treatment endpoints.
Objective To determine whether brain tau deposition, measured by 18F-PI-2620 tau-PET, is associated with fluid biomarkers, regional atrophy, and cognition in PSP. We hypothesized that increased subcortical tau uptake correlates with elevated fluid biomarkers and explored its relationship with brain volume and cognition, providing insights into disease progression.
Design Cross-sectional analysis of baseline data from the SEL003 clinical trial of sodium selenate for PSP, conducted from July 2021 to August 2024.
Setting Multicentre study across six clinical sites in Australia.
Participants 28 patients with probable PSP (Richardson’s syndrome) and 11 age- and sex-matched healthy controls from the Monash University Brain and Cognitive Health (BACH) study. Patients were over 40 years old, had symptom onset within five years, and had no structural abnormalities on MRI.
Exposures 18F-PI-2620 tau-PET, MRI, and cognitive testing were conducted in all patients. A subset of 24 patients and 10 healthy controls had blood and CSF samples analysed for NfL, GFAP, and t-tau.
Main Outcome and Measures Associations between tau-PET uptake, fluid biomarkers (NfL, GFAP, t-tau, NfL/t-tau, GFAP/t-tau, GFAP/NfL), brain volume, and cognition. Secondary outcomes included group differences (patients vs controls) in fluid biomarkers. Standardized uptake value ratio (SUVr) values were calculated using cerebellar grey matter as the reference. Cognitive testing was performed using a battery of tests.
Results Among 28 patients (median [IQR] age, 66 [62-70] years; 43% females), subcortical tau uptake was significantly associated with elevated NfL/t-tau (β=0.01; 95% CI, -0.01-0.02), reduced GFAP/NfL (β=-0.02; 95% CI, -0.01--0.01), reduced brain volume, and executive function impairment. Patients exhibited higher fluid biomarker levels in both plasma and CSF compared to controls (median [IQR] age, 65 [62-68] years; 60% female), particularly in biomarker ratios (NfL/t-tau: 98.9%, 95% CI 96.16%-100%).
Conclusions and Relevance These findings highlight the utility of 18F-PI-2620 as an in-vivo biomarker of tau pathology in PSP, with fluid biomarkers serving as valuable surrogate markers. Integrating both could improve diagnostic accuracy and treatment evaluation.
Trial Registration: Australian New Zealand Clinical Trials Registry (ACTRN12620001254987).
Key points Question: Is tau accumulation, as measured by 18F-PI-2620 tau-PET, associated with fluid biomarkers, brain volume, and cognitive function in patients with progressive supranuclear palsy (PSP)?
Findings: In this cross-sectional study of 28 patients with probable PSP, subcortical tau uptake correlated positively with NfL levels and NfL/t-tau ratios, and negatively with GFAP levels and GFAP/NfL ratios in CSF and plasma. Tau-PET was associated with lower brain volume and cognitive impairments.
Meaning: These findings suggest that 18F-PI-2620 tau-PET is a valuable tool for assessing tau pathology and its relationship with neurodegeneration and clinical outcomes in PSP. Fluid biomarker ratios may serve as surrogate markers in future clinical trials.
Competing Interest Statement
Conflict of Interest Disclosures: TOB reported receiving consulting fees to the institution from UCB, Livanova, GSK, and Eisai outside the submitted work. LV reported receiving consulting fees from Steminent Biotherapeutics outside the submitted work. No other disclosures were reported.
Clinical Trial
ACTRN12620001254987
Funding Statement
This study was funded by a Medical Research Future Fund grant from the Australian Government to TOB and LV (MRF1200254). TOB is supported by a National Health and Medical Research Council (NHMRC) Investigator grant (grant number APP1176426). RD was supported by a Monash University and an Australian Postgraduate Scholarship. MPP is supported by a NHMRC Investigator Grant (GTN2009264) and the BACH cohort study is funded by the NHMRC (GTN2009264; GTN1158384), Alzheimers Association (AARG-NTF-22-971405), Brain Foundation, and Monash University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Informed written consent was obtained from all patients or their legal representatives, and from the caregiver. Ethics approval was granted by the Alfred Health and Monash University Human Research Ethics Committee, Melbourne (594/20, SEL003; HREC/69184/Alfred-2020; BACH, 532/21, AH).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data is part of an ongoing randomized controlled trial, thus will not be available immediately. Data will be available in the future following reasonable academic requests and ethics approval. Enquires should be directed to the corresponding author.
